CN110917271A - Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers - Google Patents
Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers Download PDFInfo
- Publication number
- CN110917271A CN110917271A CN201911167225.5A CN201911167225A CN110917271A CN 110917271 A CN110917271 A CN 110917271A CN 201911167225 A CN201911167225 A CN 201911167225A CN 110917271 A CN110917271 A CN 110917271A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- parts
- children
- allergic rhinitis
- spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 63
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 47
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 47
- 201000009961 allergic asthma Diseases 0.000 title claims abstract description 36
- 239000007921 spray Substances 0.000 title claims abstract description 32
- 239000000341 volatile oil Substances 0.000 claims abstract description 103
- 239000003814 drug Substances 0.000 claims abstract description 41
- 239000000284 extract Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 22
- 244000028821 Annona squamosa Species 0.000 claims abstract description 16
- 235000005274 Annona squamosa Nutrition 0.000 claims abstract description 16
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 13
- 235000004347 Perilla Nutrition 0.000 claims abstract description 13
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000628997 Flos Species 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims abstract description 5
- 241000220261 Sinapis Species 0.000 claims abstract description 3
- 239000009670 cang er zi wan Substances 0.000 claims abstract description 3
- 244000269722 Thea sinensis Species 0.000 claims abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 235000006463 Brassica alba Nutrition 0.000 claims description 15
- 244000140786 Brassica hirta Species 0.000 claims description 15
- 235000011371 Brassica hirta Nutrition 0.000 claims description 15
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 15
- 241001643642 Viticis Species 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 14
- 241000218671 Ephedra Species 0.000 claims description 14
- 241001018563 Nekemias grossedentata Species 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 13
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 244000046146 Pueraria lobata Species 0.000 claims description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 11
- 241001506766 Xanthium Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 240000001341 Reynoutria japonica Species 0.000 claims description 8
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 6
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 6
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000001256 steam distillation Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000675108 Citrus tangerina Species 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 1
- 229940035437 1,3-propanediol Drugs 0.000 claims 1
- 240000007651 Rubus glaucus Species 0.000 claims 1
- 235000011034 Rubus glaucus Nutrition 0.000 claims 1
- 235000009122 Rubus idaeus Nutrition 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 210000004072 lung Anatomy 0.000 abstract description 18
- 206010011224 Cough Diseases 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 241001122767 Theaceae Species 0.000 description 15
- 244000132619 red sage Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 7
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 7
- 150000002212 flavone derivatives Chemical group 0.000 description 7
- 235000011949 flavones Nutrition 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 206010052437 Nasal discomfort Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010039083 rhinitis Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 4
- 241001251949 Xanthium sibiricum Species 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 206010041232 sneezing Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 208000018680 Abdominal injury Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010061430 Arthritis allergic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 241000989077 Vitex rotundifolia Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000024710 intermittent asthma Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000024696 nocturnal asthma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers, which comprises medicinal components and auxiliary materials; the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil comprises annona squamosa seed volatile oil, pericarpium citri reticulatae volatile oil, agilawood volatile oil, perilla volatile oil, honeysuckle volatile oil and borneol; the Chinese medicinal extract is prepared from semen Sinapis Albae, flos Chrysanthemi, fructus Vitics Simplicifoliae, MAOYANMEI tea, radix Puerariae, Scutellariae radix, herba Ephedrae preparata, fructus Xanthii preparata, rhizoma Polygoni Cuspidati and Saviae Miltiorrhizae radix. The invention obtains the best medicinal formula through a large number of experimental screens, and adopts the formula resolving rule of dialectical treatment to carry out the formula according to the pathogenesis characteristics of the allergic rhinitis of the children, the whole formula has the functions of dispelling wind and dredging orifices, clearing lung and relieving cough, and has good treatment effect on the allergic asthma of the children with allergic rhinitis.
Description
Technical Field
The invention particularly relates to a spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers.
Background
Allergic Rhinitis Asthma (Combined Allergic Rhinitis and arthritis syndrome. caras) refers to the simultaneous occurrence of clinical or subclinical upper airway hypersensitivity (Allergic Rhinitis) and lower airway Allergic symptoms (Asthma), which often coexist simultaneously. Immunological and pathological changes in the upper and lower respiratory tract of allergic rhinitis asthma signs are allergic inflammation occurring in the nasal and bronchial mucosa, respectively. Inflammation of the nasal mucosa and the bronchial mucosa is very similar in the aspects of pathogenesis, genetic change, local pathological change, abnormal immune function of the organism, pathogenesis and the like.
Allergic asthma of children and teenagers is combined with the increase of the incidence rate of allergic rhinitis, repeated attack can damage lung function, aggravate airway injury and the like, serious influence is caused on the learning, daily activities and even growth and development of children patients, and heavy burden is brought to families and society.
The existing medicines mainly use nasal hormones, oral or nasal antihistamines and the like for treatment, the long-term effect is not ideal, and the side effect is large after long-term application.
Disclosure of Invention
The invention aims to provide a spray which is convenient to carry and use, can effectively improve the physical condition of allergic children and can safely and effectively treat allergic rhinitis and asthma of children.
In order to achieve the above purpose, the invention adopts the following specific technical scheme:
a spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers comprises medicinal components and auxiliary materials;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
annona squamosa seed volatile oil, pericarpium citri reticulatae volatile oil, agilawood volatile oil, perilla volatile oil, honeysuckle volatile oil and borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
semen Sinapis Albae, flos Chrysanthemi, fructus Vitics Simplicifoliae, MAOYANMEI tea, radix Puerariae, Scutellariae radix, herba Ephedrae preparata, fructus Xanthii preparata, rhizoma Polygoni Cuspidati and Saviae Miltiorrhizae radix.
Preferably, the spray for preventing and treating allergic asthma combined with allergic rhinitis of children and teenagers comprises pharmaceutical ingredients and auxiliary materials;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
3-12 parts of annona squamosa seed volatile oil, 3-12 parts of dried orange peel volatile oil, 1-6 parts of agilawood volatile oil, 2-8 parts of perilla volatile oil, 3-12 parts of honeysuckle volatile oil and 1-3 parts of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
5-15 parts of white mustard seed, 6-18 parts of chrysanthemum, 5-15 parts of fructus viticis, 5-15 parts of ampelopsis grossedentata tea, 5-15 parts of kudzu vine root, 6-18 parts of scutellaria baicalensis, 5-15 parts of sealed ephedra, 3-9 parts of fried cocklebur fruit, 3-9 parts of polygonum cuspidatum and 3-9 parts of salvia miltiorrhiza.
Preferably, the spray for preventing and treating allergic asthma combined with allergic rhinitis of children and teenagers comprises pharmaceutical ingredients and auxiliary materials;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
9 parts of sweetsop seed volatile oil, 6 parts of dried orange peel volatile oil, 3 parts of agilawood volatile oil, 6 parts of perilla volatile oil, 6 parts of honeysuckle volatile oil and 1 part of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
10 parts of white mustard seed, 18 parts of chrysanthemum, 10 parts of fructus viticis, 15 parts of ampelopsis grossedentata tea, 15 parts of kudzuvine root, 12 parts of baical skullcap root, 15 parts of honey-fried ephedra herb, 6 parts of fried cocklebur fruit, 6 parts of giant knotweed rhizome and 6 parts of danshen root.
The invention relates to a spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers, wherein auxiliary materials comprise ethanol, 1, 3-propylene glycol and purified water. Wherein the volume ratio of the 1, 3-propylene glycol to the purified water is 1-2: 1-2: 10.
Preferably, the spray for preventing and treating allergic asthma combined with allergic rhinitis of children and teenagers comprises 5-15 wt% of medicinal components. The invention adopts physical pressure or spraying mode commonly used in the market to administer the medicine.
The spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers is prepared by extracting annona squamosa seed volatile oil, dried orange peel volatile oil, agilawood volatile oil, perilla volatile oil and honeysuckle volatile oil by a steam distillation method or a supercritical extraction method. Wherein during the extraction by the steam distillation method, 8-10 times of water is added, a steam distillation device is adopted for extraction for 2 hours, and the volatile oil is collected.
The invention relates to a spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers, wherein a preparation method of a traditional Chinese medicine extract comprises the following steps:
according to the weight ratio, white mustard seed, chrysanthemum, fructus viticis, maoyanmei tea, kudzu root, scutellaria baicalensis, dense ephedra herb, fried cocklebur fruit, polygonum cuspidatum and salvia miltiorrhiza are taken, water which is 6-15 times of the total weight of the medicinal materials is added, the decoction and the extraction are carried out for 1-2 times, 1-1.5 hours each time, and the extract is combined and concentrated to obtain the traditional Chinese medicine composition.
Preferably, the preparation method of the Chinese medicinal extract comprises the following steps:
according to the weight ratio, white mustard seed, chrysanthemum, fructus viticis, maoyanmei tea, kudzuvine root, baical skullcap root, fried siberian cocklebur fruit, dense ephedra herb, giant knotweed rhizome and danshen root are taken, water which is 10 times of the total weight of the medicinal materials is added for the first time, the mixture is decocted and extracted for 1.5 hours, water which is 8 times of the total weight of the medicinal materials is added for the second time, the decoction and extraction are carried out for 1 hour, and the extracting solution.
The invention utilizes the white mustard seeds through long-term tests, and the white mustard seeds are pungent, warm and nontoxic in taste. It enters nose. It is effective in removing pathogenic qi from kidney, inducing nine orifices, improving eyesight and ear, calming middle energizer, warming lung, eliminating phlegm, and invigorating qi. Can be used for treating cough and asthma due to cold phlegm, distending pain in chest and hypochondrium, phlegm stagnation in channels and collaterals, numbness and pain of joints, phlegm dampness and fluid injection, and carbuncle of yin and swelling.
Chrysanthemum flower enters lung and liver meridians. Has the effects of dispelling wind and heat, calming liver, improving eyesight, clearing away heat and toxic materials, and the like. The main treatment is as follows: wind-heat type common cold, fever, headache, conjunctival congestion, blurred vision, wind-dispelling and heat-clearing, liver-fire-purging, heat-clearing and toxicity-removing, etc.
Vitex rotundifolia is pungent and bitter in flavor and slightly cold in nature. It enters lung, bladder and liver meridians. The light-floating powder is pungent in property and capable of dispelling wind, clearing heat with slight cold, floating upward, mainly dispersing pathogenic factors of head and face, and has the effects of dispelling wind and relieving pain, and is used for treating wind-heat common cold, headache and dizziness.
The invention discloses an innovative Ampelopsis grossedentata tea which is a vine tea variety growing and multiplying in special geographical and climatic environments in Zhang Jiajie and belongs to deciduous vine plants (Vitaceae). Through detection and identification, the plant contains a natural plant cream, the main active ingredient of the plant cream is flavone, the content of crude flavone is 12.8-13.8, the average content of total flavone is more than or equal to 6%, and the highest detection content is 9.37%, so that the plant cream is the highest flavone content in all found plants at present, and is called as the king of flavone (the flavone is known as blood vessel cleaner in the medical field and is a new favorite for preventing cardiovascular and cerebrovascular diseases). The ampelopsis grossedentata tea is rich in 17 amino acids and 14 trace elements such as potassium, calcium, iron, zinc, selenium and the like, and the dihydromyricetin serving as the main flavone component of the ampelopsis grossedentata tea has the functions of sterilizing, resisting inflammation, clearing away heat and toxic materials, relieving pain, diminishing swelling, moistening throat, relieving cough, improving human immunity, resisting allergy and the like.
Kudzu root, sweet, pungent and cool. Has the functions of expelling pathogenic factors from muscles, allaying fever, promoting eruption, promoting the production of body fluid to quench thirst, invigorating yang and stopping diarrhea. It is commonly indicated for exterior syndrome with fever, stiffness and pain of neck and back, measles without adequate eruption, thirst due to fever, diabetes due to yin deficiency, dysentery due to heat-purging and diarrhea due to spleen deficiency.
Baikal skullcap root, radix Scutellariae clears away heat and toxic material and eliminates dampness, is mainly used for warm diseases, and is used for fever due to damp-warm, chest distress, thirst and no desire to drink and the like aiming at the heat quality of children.
Cang Er Zi is pungent, bitter, warm in nature and toxic. It enters lung meridian. Has the functions of dispelling wind and eliminating dampness, and dredging orifices and relieving pain, and is mainly used for treating: disperse wind-cold, unblock nasal orifices, dispel wind-damp.
The herba Ephedrae mainly contains ephedrine, has warm nature, pungent and slightly bitter taste, has effects of inducing sweat, dispelling cold, dispersing lung qi, relieving asthma, inducing diuresis and relieving swelling, and can be used for treating wind-cold type common cold, chest distress, cough, and edema, and bronchial asthma.
Hu Zhang is slightly bitter in flavor and cold in nature, and enters liver, gallbladder and lung meridians. Has effects of promoting diuresis, removing jaundice, clearing heat, detoxicating, removing blood stasis, relieving pain, relieving cough, eliminating phlegm and Germany, and can be used for treating cough due to lung heat, rheumatalgia, carbuncle, suppurative sore, scald due to hot water and fire, amenorrhea, abdominal mass, and injury due to fuzhu.
The salvia miltiorrhiza contains tanshinone, is a strong menstrual flow inducing agent, has the effects of removing blood stasis, promoting tissue regeneration, activating blood and the like, is beneficial to activating blood, and has better auxiliary effect on lung asthma, allergy and the like.
And adding Annona squamosa seed volatile oil, pericarpium Citri Tangerinae volatile oil, lignum Aquilariae Resinatum volatile oil, Perillae herba volatile oil, flos Lonicerae volatile oil and Borneolum Syntheticum, and has antibacterial, antiallergic, resuscitation inducing, antitussive, and immunity improving effects.
The above medicinal components are compatible with the specific volatile oil, so that the effects of dispelling wind and eliminating dampness, dredging orifices, detoxifying, resisting allergy, ventilating lung and relieving asthma, promoting diuresis and tonifying spleen and the like can be achieved, and the Chinese medicinal composition has a good prevention and treatment effect on allergic asthma and allergic rhinitis of children and teenagers.
Has the advantages that: according to the pathogenesis characteristics of allergic asthma combined allergic rhinitis of children and teenagers, the volatile oil component and the preferred traditional Chinese medicine extract component which are preferably composed are adopted, so that the traditional Chinese medicine composition has the characteristics of dispelling wind and freeing orifices, ventilating lungs and relieving asthma, dispelling wind, eliminating pathogenic factors, detoxifying, cooling blood and activating blood, can relieve exogenous pathogenic factors and ventilate the orifices, achieves the effect of freeing the orifices, has good effect of resisting the allergic asthma combined rhinitis, is easier to absorb by nasal capillaries and lungs of the noses through nasal spray of the volatile component and the traditional Chinese medicine extract, and has quick response.
Detailed Description
The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.
In the following examples, annona squamosa seed volatile oil, dried orange peel volatile oil, agilawood volatile oil, perilla volatile oil and honeysuckle flower volatile oil are prepared by the following methods:
respectively placing dried Annona squamosa Linn seed, pericarpium Citri Tangerinae, lignum Aquilariae Resinatum, folium Perillae or flos Lonicerae in volatile oil extractor, respectively adding 10 times of water, extracting for 2 hr by steam distillation, and respectively collecting to obtain litchi seed volatile oil, pericarpium Citri Tangerinae volatile oil, lignum Aquilariae Resinatum volatile oil, Perillae herba volatile oil and flos Lonicerae volatile oil.
Example 1
A spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers comprises medicinal components and adjuvants (ethanol: 1, 3-propylene glycol: purified water volume ratio 1: 2: 10); wherein the weight percentage of the medicine components is 8 percent;
the medicinal components are prepared from volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared by combining the following components:
9g of sweetsop seed volatile oil, 6g of dried orange peel volatile oil, 3g of agilawood volatile oil, 6g of perilla volatile oil, 6g of honeysuckle volatile oil and 1g of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
10g of white mustard seed, 18g of chrysanthemum, 10g of fructus viticis, 15g of Ampelopsis grossedentata tea, 15g of kudzuvine root, 12g of baical skullcap root, 15g of dense ephedra herb, 6g of fried siberian cocklebur fruit, 6g of giant knotweed rhizome and 6g of salvia miltiorrhiza.
The traditional Chinese medicine extracts are prepared by the following method:
according to the weight ratio, 10g of white mustard seed, 18g of chrysanthemum, 10g of fructus viticis, 15g of ampelopsis grossedentata tea, 15g of radix puerariae, 12g of radix scutellariae, 15g of compact ephedra herb, 6g of fried cocklebur fruit, 6g of polygonum cuspidatum and 6g of salvia miltiorrhiza are taken, water which is 10 times of the total weight of the medicinal materials is added for the first time, the mixture is decocted and extracted for 1.5 hours, water which is 8 times of the total weight of the medicinal materials is added for the second time, the decoction and extraction is carried out for 1 hour.
Example 2
A spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers comprises medicinal components and adjuvants (ethanol: 1, 3-propylene glycol: purified water volume ratio 1: 2: 10); wherein the weight percentage of the medicine components is 8 percent;
the medicinal components are prepared from volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared by combining the following components:
3g of sweetsop seed volatile oil, 6g of tangerine peel volatile oil, 1g of agilawood volatile oil, 6g of perilla volatile oil, 6g of honeysuckle volatile oil and 1g of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
5g of white mustard seed, 18g of chrysanthemum, 5g of fructus viticis, 5g of Ampelopsis grossedentata tea, 15g of kudzuvine root, 12g of baical skullcap root, 15g of dense ephedra herb, 6g of fried siberian cocklebur fruit, 6g of giant knotweed rhizome and 6g of salvia miltiorrhiza.
The traditional Chinese medicine extracts are prepared by the following method:
according to the weight ratio, 5g of white mustard seed, 18g of chrysanthemum, 10g of fructus viticis, 5g of ampelopsis grossedentata tea, 15g of radix puerariae, 12g of radix scutellariae, 15g of dense ephedra herb, 6g of fried cocklebur fruit, 6g of polygonum cuspidatum and 3g of salvia miltiorrhiza are taken, water which is 10 times of the total weight of the medicinal materials is added for the first time, the mixture is decocted and extracted for 2 hours, water which is 8 times of the total weight of the medicinal materials is added for the second time, the decoction and extraction are carried out for 1 hour.
Comparative example 1
A spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers comprises medicinal components and adjuvants (ethanol: 1, 3-propylene glycol: purified water volume ratio 1: 2: 10); wherein the weight percentage of the medicine components is 8 percent;
the medicinal components are volatile oil: the volatile oil is prepared by combining the following components:
9g of sweetsop seed volatile oil, 6g of tangerine peel volatile oil, 2g of agilawood volatile oil, 6g of perilla volatile oil, 6g of honeysuckle volatile oil and 1g of borneol.
Comparative example 2
A spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers comprises medicinal components and adjuvants (ethanol: 1, 3-propylene glycol: purified water volume ratio 1: 2: 10); wherein the weight percentage of the medicine components is 8 percent;
the traditional Chinese medicine extract is prepared from the following raw materials:
10g of white mustard seed, 18g of chrysanthemum, 10g of fructus viticis, 15g of Ampelopsis grossedentata tea, 15g of kudzuvine root, 12g of baical skullcap root, 15g of dense ephedra herb, 6g of fried siberian cocklebur fruit, 6g of giant knotweed rhizome and 6g of salvia miltiorrhiza.
The traditional Chinese medicine extracts are prepared by the following method:
according to the weight ratio, 10g of white mustard seed, 18g of chrysanthemum, 10g of fructus viticis, 15g of ampelopsis grossedentata tea, 15g of radix puerariae, 12g of radix scutellariae, 15g of compact ephedra herb, 6g of fried cocklebur fruit, 6g of polygonum cuspidatum and 6g of salvia miltiorrhiza are taken, water which is 10 times of the total weight of the medicinal materials is added for the first time, the mixture is decocted and extracted for 1.5 hours, water which is 8 times of the total weight of the medicinal materials is added for the second time, the decoction and extraction is carried out for 1 hour.
Example 3 clinical Observation experiment of allergic asthma with allergic rhinitis
(1) Allergic asthma combined with allergic rhinitis tested case selection: according to the diagnosis standards of allergic asthma and allergic rhinitis (the diagnosis standard of allergic asthma, namely bronchial asthma prevention and treatment guidelines (2008) formulated by the respiratory disease institute of Chinese medical society of asthma, 40 cases of patients suffering from allergic asthma and allergic rhinitis are randomly divided into a treatment group of an embodiment 1 and a treatment group of an embodiment 2 and a control group of 1, wherein the control group of the control group is 2, the 40 cases of patients suffering from allergic asthma and allergic rhinitis comprise 22 male patients and 18 female patients, the age of the patients is 3-15 years, and the average age of the patients is 8 +/-1.2 years.
(3) The treatment method comprises the following steps: the treatment groups sprayed the sprays of example 1 and example 2 respectively 3 times daily with 2ml each time. Spraying the spray of control group 1 and control group 2 3 times daily, 2ml each time, respectively for control group 1 and control group 2. The evaluation of the treatment effect is carried out 3 months after the medicine is taken.
(4) Evaluation of therapeutic effect: after 1 month of treatment, the effect of treatment was observed.
① the standard of the asthma control score is that the score of the asthma control is 25, the score of the asthma control is good is 20-24, and the score of the asthma control is not less than 20.
② rhinitis symptom scoring standard A. the symptoms of the patients are evaluated according to the allergic rhinitis scoring standard in 'pocket-size reference for allergic rhinitis treatment 2009'.
Rqlq rating scale: scoring was performed before and after treatment.
③ serum total IgE detection, namely fasting venous blood, and the content of IgE detected by the kit.
④ evaluation index of curative effect of allergic rhinitis, wherein the improvement rate is calculated by [ (total fraction before treatment-total fraction after treatment)/total fraction before treatment ] & gt 100%, wherein the significant effect is larger than or equal to 51%, the effective effect is larger than or equal to 50%, and is larger than or equal to 21%, and the ineffective effect is smaller than or equal to 20%.
⑤ has effective total effective rate, namely the effective rate is that the asthma score is more than 20 and the allergic rhinitis curative effect evaluation index is equal to or larger than 51 percent, the improvement rate is that the asthma score is 20-24 and the allergic rhinitis curative effect evaluation index is equal to or larger than 50 percent and equal to or larger than 21 percent, and the ineffective rate is that the asthma score is less than 20 and the allergic rhinitis curative effect evaluation index is equal to or smaller than 20 percent.
(5) As a result: the collected data were statistically analyzed using SPSS 18.0 software. Asthma control score, rhinitis symptoms score results are shown in table 1, RQLQ score and serum total IgE indicator results are shown in table 2. The results show that examples 1 and 2 of the present invention have better efficacy in treating asthma and rhinitis than the control group of examples 1 and 2.
The effective rate of example 1 is 90%, and the effective rate of the treatment group in example 2 is 80% which is significantly higher than that of the control group 1 (effective rate is 20%) and the control group 2 (effective rate is 30%), and the specific results are shown in table 3.
Table 1 comparison of the asthma control scores and rhinitis symptom scores for two groups of patients before and after treatment (score,
)
p <0.001 compared to before treatment, P <0.05 compared to before treatment
Table 2 comparison of RQLQ scores and serum total IgE scores for two groups of patients before and after treatment (score,
)
p <0.001 compared to before treatment, P <0.05 compared to before treatment
TABLE 3 comparison of the Total effects of treatment in two groups of patients (examples)
| Group of | Number of examples | Is effective | Improvement of life | Invalidation | Total effective rate |
| Example 1 | 10 | 8 | 1 | 1 | 90％ |
| Example 2 | 10 | 7 | 3 | 2 | 80％ |
| Comparative example 1 | 10 | 0 | 2 | 8 | 20％ |
| Comparative example 2 | 10 | 0 | 3 | 7 | 30％ |
。
The clinical test results show that the spray provided by the invention has a good treatment effect on allergic asthma combined with allergic rhinitis, and a comparison experiment shows that the treatment effect is reduced when the contents of sweetsop seed volatile oil, agilawood volatile oil and semen brassicae, fructus viticis and Ampelopsis grossedentata are reduced. When the amount of the spraying agent is the same, when the spraying agent is compared with a single volatile oil component or a single traditional Chinese medicine extract component, the volatile oil and the traditional Chinese medicine extract are combined, the effect of treating allergic asthma combined allergic rhinitis is more remarkable, and the components supplement each other to play a role in synergistic promotion.
Example 4 Experimental observations on asthma model mice
(1) Reagent and experimental medicine
IL-5 and IL-13 kits were purchased from Hangzhou Union Biotechnology, Inc.
The tested drugs are: example 1, example 2, comparative example 1 and comparative example 2, administered by nebulization;
(2) laboratory animal
Km mice, 4-6 weeks old, female, SPF grade, provided by the Qinglongshan animal breeding farm in Jiangning district, Nanjing.
(3) Experimental methods
(3.1) Molding
Mice were randomly divided into 6 groups, normal group, model group, example 1, example 2, control group 1, and control group 2. After procurement, the model group, example 1, example 2, control group 1 and control group 2 were sensitized by intraperitoneal injection of 0.4ml of OVA sensitizing solution (prepared from OVA2g, 20ml of aluminum hydroxide gel and 20ml of physiological saline) on day 0 and day 7, respectively, and the normal group was sensitized by intraperitoneal injection of an equal amount of physiological saline. And starting atomizing and inhaling 5% OVA solution for 30min on day 14, and continuously atomizing for 5d, 1 time per day, 30min each time. The normal mice were nebulized with an equal amount of physiological saline.
(3.1) administration of drugs
Example 1, example 2, control 1 and control 2 were administered by nebulization spray 2ml each time, 3 times daily for 7 days.
(3.2) Collection of Experimental specimens
After 24h of the last atomization (during which mice were fasted without water), blood was taken from the eyeballs after anesthesia, and then killed by cervical dislocation. 4 of them were frozen at-80 deg.C with alveolar lavage fluid; in addition, 4 of the other lungs were cut and fixed in 4% paraformaldehyde, and the remaining lung tissue was kept at-80 ℃ for further use.
(4) Results of the experiment
(4.1) pathological inflammation conditions of the lung: compared with the normal group, the model group has obvious starred thickening of the bronchial tube wall, thickening of the alveolar wall and inflammatory cell infiltration. After the spray of the invention in example 1 and example 2 is administered, the inflammatory infiltration of lung tissue, the secretion of lumen and the like of mice are obviously reduced, and the effect of example 1 is better than that of example 2, while the inflammatory infiltration of lung tissue, the secretion of lumen and the like of mice in comparative examples 1 and 2 are reduced but not obvious.
(4.2) expression of IL-4, IL-5, and IL-13 inflammatory factors in alveolar lavage fluid.
Specific results are shown in Table 4, and compared with the normal group, the IL-4, IL-13 and IL-5 levels in the model group are obviously increased, the IL-4, IL-13 and IL-5 levels are obviously reduced after the spray of example 1 and 2 are given, and the difference has statistical significance (P < 0.05). While comparative examples 1 and 2 had some effect of reducing IL-13 and IL-5 levels, but did not have statistical significance (P > 0.05).
TABLE 4 expression of IL-4, IL-5, and IL-13 inflammatory factors in each group
| Group of | IL-5(pg/mL) | IL-4(ng/mL) | IL-13(pg/mL) |
| Normal group | 53 | 23 | 40 |
| Model set | 138# | 43# | 68# |
| Example 1 | 60** | 26* | 45* |
| Example 2 | 63** | 27* | 48* |
| Comparative example 1 | 86 | 37 | 59 |
| Comparative example 2 | 80 | 35 | 56 |
Compared with the normal group, P <0.05 compared with before treatment
Example 5
Case one
In xxx, female, 7 years old
The main complaints are: the nasal itching and nasal obstruction are intercropped for 1 year.
The current medical history: the infant patient has repeated nasal itching and nasal obstruction for 2 years, sneezing, nasal itching and nasal obstruction in the morning, and cough and asthma aggravation at night, which are occasionally seen. Insomnia, constipation 1-2 days, 1 time, and dryness.
Physical examination: tonsil II degree swelling, and lymphoid follicle hyperplasia in the posterior pharyngeal wall. The tongue is dark red and white.
And (3) diagnosis: western medicine: allergic rhinitis with asthma
Prescription: spray the solution of example 13 times daily with 2mL each time.
The nasal itching and the nasal obstruction are rechecked after 4 weeks of continuous spraying treatment, the cough and asthma at night are obviously improved compared with the cough and asthma at night, the appetite is good, the stool is adjusted, and the tongue is dark and reddish.
Case two
Li xxx, male, half age 6
The main complaints are: itchy nose, sneezing with watery nasal discharge for more than 3 months, with nocturnal asthma and cough.
The current medical history: the infant has rhinocnesmus and sneezing in about 3 months, and has intermittent asthma and cough, insomnia and dry stool in night.
Physical examination: the lung auscultation respiratory sound is normal. The tongue is red with thin and white coating.
And (3) diagnosis: western medicine: allergic rhinitis is associated with asthma.
Prescription: spray the solution of example 13 times daily with 2mL each time.
After 4 weeks of continuous spray treatment: the infant suffered from sneezing, nasal itching, cough alleviation, watery nasal discharge, insomnia, convenient adjustment, red tongue and thin tongue coating.
Claims (7)
1. A spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers is characterized by comprising medicinal components and auxiliary materials;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
annona squamosa seed volatile oil, pericarpium citri reticulatae volatile oil, agilawood volatile oil, perilla volatile oil, honeysuckle volatile oil and borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
semen Sinapis Albae, flos Chrysanthemi, fructus Vitics Simplicifoliae, MAOYANMEI tea, radix Puerariae, Scutellariae radix, herba Ephedrae preparata, fructus Xanthii preparata, rhizoma Polygoni Cuspidati and Saviae Miltiorrhizae radix.
2. The spray for preventing and treating allergic asthma complicated with allergic rhinitis in children and teenagers as claimed in claim 1, which comprises pharmaceutical ingredients and adjuvants;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
3-12 parts of annona squamosa seed volatile oil, 3-12 parts of dried orange peel volatile oil, 1-6 parts of agilawood volatile oil, 2-8 parts of perilla volatile oil, 3-12 parts of honeysuckle volatile oil and 1-3 parts of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
5-15 parts of white mustard seed, 6-18 parts of chrysanthemum, 5-15 parts of fructus viticis, 5-15 parts of ampelopsis grossedentata tea, 5-15 parts of kudzu vine root, 6-18 parts of scutellaria baicalensis, 5-15 parts of sealed ephedra, 3-9 parts of fried cocklebur fruit, 3-9 parts of polygonum cuspidatum and 3-9 parts of salvia miltiorrhiza.
3. The spray for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers as claimed in claim 2, wherein,
it comprises medicinal components and auxiliary materials;
the medicinal components comprise volatile oil and traditional Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
9 parts of sweetsop seed volatile oil, 6 parts of dried orange peel volatile oil, 3 parts of agilawood volatile oil, 6 parts of perilla volatile oil, 6 parts of honeysuckle volatile oil and 1 part of borneol;
the traditional Chinese medicine extract is prepared from the following raw materials:
10 parts of white mustard seed, 18 parts of chrysanthemum, 10 parts of fructus viticis, 15 parts of ampelopsis grossedentata tea, 15 parts of kudzuvine root, 12 parts of baical skullcap root, 15 parts of honey-fried ephedra herb, 6 parts of fried cocklebur fruit, 6 parts of giant knotweed rhizome and 6 parts of salvia miltiorrhiza.
4. The spray for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers as claimed in any one of claims 1 to 3, wherein the adjuvant comprises ethanol, 1, 3-propanediol, and purified water.
5. The spray for preventing and treating allergic asthma combined with allergic rhinitis of children and teenagers according to any one of claims 1 to 3, wherein the annona squamosa seed volatile oil, the dried tangerine peel volatile oil, the agilawood volatile oil, the perilla volatile oil and the honeysuckle volatile oil are extracted by a steam distillation method or a supercritical extraction method.
6. The spray for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers as claimed in any one of claims 1 to 3, wherein the preparation method of the Chinese medicinal extract comprises the steps of:
taking semen brassicae, chrysanthemum, fructus viticis, maoyan raspberry tea, radix puerariae, dense-prepared scutellaria baicalensis ephedra, fried cocklebur fruit, polygonum cuspidatum and salvia miltiorrhiza according to the weight ratio, adding water which is 6-15 times of the total weight of the medicinal materials, decocting and extracting for 1-2 times, 1-1.5 hours each time, combining extracting solutions, and concentrating to obtain the traditional Chinese medicine composition.
7. The spray for preventing and treating allergic asthma complicated with allergic rhinitis in children and teenagers as claimed in claim 6, wherein the preparation method of the herbal extract comprises the steps of:
according to the weight ratio, white mustard seed, chrysanthemum, fructus viticis, maoyanmei tea, kudzu root, scutellaria baicalensis, dense ephedra herb, fried cocklebur fruit, polygonum cuspidatum and salvia miltiorrhiza are taken, water which is 10 times of the total weight of the medicinal materials is added for the first time, the mixture is decocted and extracted for 1.5 hours, water which is 8 times of the total weight of the medicinal materials is added for the second time, the decoction and extraction are carried out for 1 hour, and the extracting solutions are combined and concentrated to obtain.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911167225.5A CN110917271A (en) | 2019-11-25 | 2019-11-25 | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers |
| PCT/CN2020/116449 WO2021103777A1 (en) | 2019-11-25 | 2020-09-21 | Spraying agent for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911167225.5A CN110917271A (en) | 2019-11-25 | 2019-11-25 | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917271A true CN110917271A (en) | 2020-03-27 |
Family
ID=69851014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911167225.5A Pending CN110917271A (en) | 2019-11-25 | 2019-11-25 | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110917271A (en) |
| WO (1) | WO2021103777A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021103777A1 (en) * | 2019-11-25 | 2021-06-03 | 垒途智能教科技术研究院江苏有限公司 | Spraying agent for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130216574A1 (en) * | 2012-02-20 | 2013-08-22 | James Liu | Kit providing multiple unmet therapeutic effects |
| CN104548024A (en) * | 2015-01-06 | 2015-04-29 | 山东省中医药研究院 | Externally-applied medicine for treating combined allergic rhinitis and asthma syndrome |
| CN107753664A (en) * | 2017-12-01 | 2018-03-06 | 大连大学 | A kind of Chinese medicine composition for treating allergic rhinitis and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100389792C (en) * | 2005-01-17 | 2008-05-28 | 佛山德众药业有限公司 | Pharmaceutical composition for treating nose disease and its preparation method |
| CN101612280B (en) * | 2009-07-16 | 2011-05-11 | 杨立光 | Paste for treating rhinitis and nasosinusitis |
| CN108114040A (en) * | 2018-01-16 | 2018-06-05 | 成都市飞龙水处理技术研究所青白江第分所 | It is a kind of to be used to treat capsule medicine of allergic rhinitis and preparation method thereof |
| CN110917271A (en) * | 2019-11-25 | 2020-03-27 | 垒途智能教科技术研究院江苏有限公司 | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers |
-
2019
- 2019-11-25 CN CN201911167225.5A patent/CN110917271A/en active Pending
-
2020
- 2020-09-21 WO PCT/CN2020/116449 patent/WO2021103777A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130216574A1 (en) * | 2012-02-20 | 2013-08-22 | James Liu | Kit providing multiple unmet therapeutic effects |
| CN104548024A (en) * | 2015-01-06 | 2015-04-29 | 山东省中医药研究院 | Externally-applied medicine for treating combined allergic rhinitis and asthma syndrome |
| CN107753664A (en) * | 2017-12-01 | 2018-03-06 | 大连大学 | A kind of Chinese medicine composition for treating allergic rhinitis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曹红九等: "哮喘停喷雾剂治疗支气管哮喘临床观察", 《中国中医急症》 * |
| 曾莺: "加用宣肺平喘通窍方治疗儿童哮喘并变应性鼻炎的疗效观察", 《广西中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021103777A1 (en) * | 2019-11-25 | 2021-06-03 | 垒途智能教科技术研究院江苏有限公司 | Spraying agent for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021103777A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN112675278A (en) | Composition for moistening lung to arrest cough and inhibiting lung inflammatory reaction and preparation method and application thereof | |
| CN104800382A (en) | Traditional Chinese medicine composition for treating colds, as well as preparation method and application thereof | |
| WO2021208336A1 (en) | Traditional chinese medicine composition and use thereof | |
| CN110917271A (en) | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers | |
| WO2023125798A1 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
| CN104257763A (en) | Aqueous extract of cistanche deserticola, and preparation method and application thereof | |
| CN116115689A (en) | Seven-orifice rhinitis-relieving spray and preparation method thereof | |
| CN111407808B (en) | Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof | |
| CN100353985C (en) | Medicine with cough and asthma stopping and lung moistening functions and its preparation process | |
| CN107753664B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
| CN112316034A (en) | Externally-applied traditional Chinese medicine composition for treating chronic pharyngitis as well as preparation method and application thereof | |
| CN105250968A (en) | Traditional Chinese medicine preparation for treating asthma | |
| CN104208168B (en) | A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof | |
| CN106110156A (en) | A kind of cream side for chronic obstructive pulmonary disease, preparation method and its usage | |
| CN105727069A (en) | Medicinal composition for treating chronic cholecystitis and preparation method for medicinal composition | |
| CN111035686A (en) | Plant source compound Chinese medicine smelling agent and preparation method thereof | |
| CN105412679A (en) | Traditional Chinese medicine preparation for treating lung abscess and preparation method thereof | |
| CN105727029A (en) | Medicine composition for treating nasal polyp and preparation method thereof | |
| CN105031339A (en) | Traditional Chinese medicine composition for treating stomatitis | |
| CN104784563A (en) | Traditional Chinese medicine preparation for treating amygdalitis and preparation method thereof | |
| CN113262289A (en) | Traditional Chinese medicine composition and preparation for treating nasal sinusitis and preparation method thereof | |
| CN104435173A (en) | Health medicinal liquor and production method thereof | |
| CN117942372A (en) | Traditional Chinese medicine preparation for treating rhinitis and pharyngitis of respiratory system | |
| CN115645488A (en) | Rhinitis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |